This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

That would be nice Mitzy, 150,

From Killik the Brokers morning notes...............

Medical Marketing

Medical Marketing, the Cambridge based pharmaceutical development company, said it has further expanded the collaboration between the University of Edinburgh and its wholly owned subsidiary Oncosense. The team developing Ruthenium anticancer complexes will now include Dr James Hoeschele - a co-inventor of the platinum based chemotherapy drug Carboplatin. Dr James Hoeschele is an acknowledged expert in the field of anti-tumour precious metal complexes. We understand that this announcement is the result of Dr Hoeschele approaching Medical Marketing to work with them and given his reputation this is a strong endorsement of the company.

Medical Marketing have moved dramatically in the last three weeks, up from around 60p to the cuurent 110p level. Newsflow from the company is expected to strong in the coming months and we believe the shares have further to go.




cheers GF.

From Killik.......................

Newsflow from the company is expected to strong in the coming months and we believe the shares have further to go.

gf.

Ill be happy to finish the week on this price, maybe more to come next,?..Jb

You bet.. next Tuesday it will take off for the Moon...

Why tuesday mitzy,??

Been a bit busy else where today so just catching up. Yes, why tuesday mitzy.

MS

Come on Mitzy spill the beans, I want Dil and his buddies to buy in.

cheers GF.

PS, dont forget either thats 4 out of 4 you hace called correctly amazing. My fellow freinds would love to know what you know.

Hi Gf.
A presentation this Tuesday in the City by Dr Best for 20 brokers and other interested parties..you can bet that after Tuesday it will rise to 150p plus..

Amazing how you get this news Mitzy keep it coming and you can be assured that I will use it to great effect.

cheers again GF.

SEE POST 253 and then think about investing in a company that as 6 or more products to report on to the market.

cheers GF.

Theres more to come gf....150p to 200p within 4 weeks..hold.

mitzy

Are you serious?

MS

Wait till March.....

Mitzy hold, you must be joking Im going to buy more, a lot more.

cheers GF

Recieved my Feb edition of Scsw today and they mention they have visited the management of three Biotech companies this month and they will reveal more next month.I'm hoping its MMI's...because they covered them 3 years ago and then dropped coverage of them.
Neteller is the January tip of the month in their portfolio..

Good news Mitzy.

cheers GF.

Expecting another 10p plus rise tomorrow ahead of Tuesdays broker presentation and if the volume continues during the rest of the week we could see 150p which is where it started back in 2001.So basically we have only begun to witness the true value of MMI's bio-babies.

Medical Marketing expands collaboration with University of Edinburgh
AFX


LONDON (AFX) - Medical Marketing International Group PLC, the Cambridge based pharmaceutical development company, said it has further expanded the collaboration between the University of Edinburgh and its wholly owned subsidiary Oncosense.

The team developing Ruthenium anticancer complexes will now include Dr James Hoeschele - a co-inventor of the platinum based chemotherapy drug Carboplatin.

Dr James Hoeschele is an acknowledged expert in the field of anti-tumour precious metal complexes, the company said.

newsdesk@afxnews.com

Superb looking chart and volumes way up.



cheers GF.